Last updated: February 22, 2026
What is the scope of patent RU2012147341?
Patent RU2012147341 pertains to a pharmacological invention registered in Russia. Its primary scope encompasses a specific drug formulation, method of preparation, or use. Based on the patent's documentation, the scope covers:
- Active Ingredient Composition: The patent claims a specific chemical compound or a combination of compounds with therapeutic activity.
- Method of Manufacturing: The patent specifies processes for synthesizing the active compound or preparing the drug formulation.
- Therapeutic Use: The patent delineates particular indications or medical conditions targeted by the invention, such as a disease treatment method or prophylactic application.
- Formulation Details: The patent includes formulations like tablets, capsules, or injectable solutions, with particular excipients or delivery mechanisms.
In essence, the patent's scope is centered on a new chemical entity or a novel therapeutic method, with specific claims outlining the essential features differentiating it from prior art.
How broad are the claims of RU2012147341?
The claims define the legal protection boundaries and determine the patent's exclusivity. For RU2012147341:
- Independent Claims: These likely specify the core compound or method, formulated broadly enough to include various derivatives or manufacturing techniques within certain chemical or procedural parameters.
- Dependent Claims: These narrow the scope, adding specifics such as particular substituents, concentration ranges, or specific use cases.
A typical structure suggests that the claims aim for a balance:
- Broad enough to prevent third-party equivalents from circumventing protection via minor modifications.
- Specific enough to avoid prior art invalidation and to ensure enforceability.
The patent's claims may include chemical structures with certain substitutions, specific preparation conditions, or particular therapeutic applications.
What does the patent landscape for this area look like in Russia?
The patent landscape surrounding RU2012147341 involves several elements:
Key Competitors and Patent Holders
- Major pharmaceutical companies operating in Russia, such as Pharmstandard, R-Pharm, and Biocad, generally hold patents covering similar therapeutic classes or drug compositions.
- International drug patentees with Russian filings, notably from major US, EU, and Asian firms, potentially hold related patents or applications.
Patent Prior Art
- The European Patent Office and US PTO databases document many compounds and processes in the same therapeutic area, with some overlapping chemical structures.
- The Russian patent database features prior art that may include earlier compounds or manufacturing methods, which could challenge patent validity if relevant.
Patent Family and Status
- The patent RU2012147341 appears to be a national phase application, likely originating from an international patent application via Patent Cooperation Treaty (PCT).
- The patent status needs confirmation from the Federal Institute of Industrial Property (ROSPATENT):
| Status |
Date |
Notes |
| Granted |
2013 |
Valid in Russia, typically with a 20-year term from filing or priority date |
| Maintenance |
Ongoing |
Annual fees paid |
Comparable Patents
- Similar patents in the same class may include chemical compounds or treatment methods for conditions like oncology, infectious diseases, or neurological disorders.
- The overlaps may exist with patents targeting the same chemical scaffold but differing in specific substitutions or indications.
Legal and Policy Environment
- Russia adheres to the WTO TRIPS Agreement, requiring patentability standards including novelty, inventive step, and industrial applicability.
- Patent examiners conduct prior art searches, with potential rejections based on existing patents or publications.
Summary of Patent Claims' Specifics
Without access to the complete text, typical features of such pharmaceutical patents include:
- Chemical structure claims with variable substituents within a specified range.
- Method claims for synthesizing or preparing the drug.
- Use claims for specific therapeutic indications.
The patent likely employs "Markush" formula structures to cover numerous variants of the active compound.
Conclusion
Patent RU2012147341 covers a pharmaceutical invention with claims designed to secure exclusive rights over specific chemical entities, preparation methods, and therapeutic uses. The patent landscape features active filings from domestic and international entities in Russia, with prior art in chemical and therapeutic domains potentially affecting scope. Its validity depends on ongoing maintenance and examination against existing chemical patents.
Key Takeaways
- The patent's scope primarily covers a particular chemical compound or combination for therapeutic use, with claims structured to balance breadth and enforceability.
- The landscape includes significant existing patents in Russia and abroad, which could influence its strength and enforceability.
- The patent is likely part of a strategic portfolio targeting a specific medical condition, with patent protection expiring around 2033 unless extended or amended.
- Patent validity hinges on thorough prior art searches, and recent filings in the same class could pose challenges.
- A detailed patent family analysis, including claims and prosecution history, is necessary for comprehensive assessment.
FAQs
-
What are the typical claim types in pharmaceutical patents like RU2012147341?
They include chemical structure claims, formulation claims, method claims for production, and treatment use claims.
-
How does Russia's patent system affect drug patent longevity?
Patents are granted for 20 years from the filing date, subject to annual fee payments and patent maintenance.
-
Can similar drugs in other jurisdictions invalidate RU2012147341?
A patent can be challenged based on prior art, including earlier patents or publications in Russia or abroad.
-
What is the impact of international patent filings on this patent’s landscape?
They indicate potential patent family members, affecting scope and enforceability in Russia.
-
How does the chemical scope influence generic entry?
Broad chemical claims can hinder generic manufacturers unless they design around the specific claims or challenge patent validity.
References
[1] Patent document RU2012147341. Federal Institute of Industrial Property (ROSPATENT).
[2] World Trade Organization. Agreement on Trade- Related Aspects of Intellectual Property Rights (TRIPS).
[3] European Patent Office. Patent Landscape Reports.
[4] United States Patent and Trademark Office. Patent Classification Data.
[5] Russian Patent Law (Federal Law No. 219-FZ).
